CFDE Data Portal | Search LOC105377489

	Label	Description
	LOC105377489 Gene (Entity type)	ENSG00000251377 - uncharacterized LOC105377489
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE149049 FLT3 inhibition 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE240741 L-13 TIME 4 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216757 decitabine fibroblast 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE209973 glutamine lung 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE221329 ERK BRAF inhibition thyroid gland 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 3 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE149049 FLT3 inhibition 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE181492 chrysin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC105377489

ENSG00000251377 - uncharacterized LOC105377489

GSE195568 palbociclib 1 v 10 human up

A Gene Set from LINCS

GSE149049 FLT3 inhibition 1 v 2 human up

A Gene Set from LINCS

GSE240741 L-13 TIME 4 v 6 human dn

A Gene Set from LINCS

GSE216757 decitabine fibroblast 0 v 2 human up

A Gene Set from LINCS

GSE209973 glutamine lung 1 v 0 human up

A Gene Set from LINCS

GSE221329 ERK BRAF inhibition thyroid gland 1 v 6 human dn

A Gene Set from LINCS

GSE195568 palbociclib 3 v 4 human dn

A Gene Set from LINCS

GSE149049 FLT3 inhibition 1 v 3 human up

A Gene Set from LINCS

GSE181492 chrysin 1 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.